Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Evista
2. Keoxifene
3. Keoxifene Hydrochloride
4. Ly 139481
5. Ly 156758
6. Ly-139481
7. Ly-156758
8. Ly139481
9. Ly156758
10. Raloxifene
11. Raloxifene Hcl
1. 82640-04-8
2. Raloxifene Hcl
3. Evista
4. Keoxifene Hydrochloride
5. Keoxifene
6. Optruma
7. Raloxifene Teva
8. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride
9. Raloxifene (hydrochloride)
10. Ly 156758
11. Ly156758
12. Ly-156758
13. Nsc-706725
14. 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol Hydrochloride
15. Chebi:50740
16. Evista (raloxifene Hydrochloride)
17. 4f86w47br6
18. 6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride
19. Dsstox_cid_14181
20. Dsstox_rid_79119
21. Dsstox_gsid_34181
22. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
23. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
24. Smr000058508
25. Raloxifene Hydrochloride [usan]
26. Ncgc00015889-05
27. Cas-82640-04-8
28. C28h27no4s.hcl
29. Loxifen
30. Unii-4f86w47br6
31. Sr-01000076102
32. Cdt-raloxifene
33. Raloxifene-d4 Hcl
34. Raloxifene Cloridrato
35. Evista (tn)
36. Mfcd01938233
37. Prestwick_1035
38. Raloxifene Hydrochloride [usan:usp]
39. Methanone, Hydrochloride
40. Cloridrato De Raloxifeno
41. Clorhidrato De Raloxifeno
42. Chlorhydrate De Raloxifene
43. Ly139481 Hydrochloride
44. Ly156758 Hydrochloride
45. Chembl1116
46. Schembl19077
47. Mls000859902
48. Mls001332533
49. Mls001332534
50. Mls002222293
51. Raloxifene Hydrochloride, Solid
52. Evista, Raloxifene Hydrochloride
53. Raloxifene Hydrochloride- Bio-x
54. Dtxsid1034181
55. Ly156758 (keoxifene) Hcl
56. Ly-139481 Hcl
57. Hms1570n05
58. Pharmakon1600-01505622
59. Amy23426
60. Bcp05713
61. Raloxifene Hydrochloride (jan/usp)
62. Tox21_110255
63. Tox21_302369
64. Tox21_501051
65. Hy-13738a
66. Nsc706725
67. Nsc759285
68. Raloxifene Hydrochloride [mi]
69. S1227
70. Raloxifene Hydrochloride [jan]
71. Akos008131940
72. Tox21_110255_1
73. Ac-8390
74. Ccg-213497
75. Cs-1775
76. Ds-2162
77. Ks-1102
78. Lp01051
79. Nc00665
80. Nsc 706725
81. Nsc 759285
82. Nsc-759285
83. Raloxifene Hydrochloride [mart.]
84. Raloxifene Hydrochloride [vandf]
85. Ncgc00015889-03
86. Ncgc00015889-11
87. Ncgc00092353-01
88. Ncgc00092353-03
89. Ncgc00094334-01
90. Ncgc00094334-02
91. Ncgc00255153-01
92. Ncgc00261736-01
93. Raloxifene Hydrochloride [usp-rs]
94. Raloxifene Hydrochloride [who-dd]
95. Br164310
96. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride
97. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)
98. Raloxifene Hydrochloride [ema Epar]
99. Eu-0101051
100. Ft-0630912
101. R0109
102. Sw197106-5
103. En300-52517
104. Raloxifene Hydrochloride [orange Book]
105. D02217
106. R 1402
107. Raloxifene Hydrochloride [ep Monograph]
108. Raloxifene Hydrochloride [usp Impurity]
109. Raloxifene Hydrochloride [usp Monograph]
110. 640r048
111. A840401
112. Q-201656
113. Sr-01000076102-2
114. Sr-01000076102-9
115. Q27122215
116. (6-oxo-1,6-dihydro-pyridazin-3-yloxy)-aceticacid
117. Raloxifene Hydrochloride, European Pharmacopoeia (ep) Reference Standard
118. Raloxifene Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
119. Raloxifene Hydrochloride, United States Pharmacopeia (usp) Reference Standard
120. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride
121. (6-oh-2-(4-oh-ph)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)ph)methanone Hydrochloride
122. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone Hydrochloride
123. [6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
124. [6-hydroxy-2-(4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
125. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
126. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone, Monohydrochloride
127. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
128. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
129. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
130. [6-hydroxy-2[4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
131. 1-[2-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]carbonyl}phenoxy)ethyl]piperidinium Chloride
132. 6-hydroxy-2-(4-hydroxyphenyl)-3-[ 4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, Hydrochloride
133. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]-thiophene Hydrochloride
134. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene Hydrochloride
135. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Methanone Hydrochloride
136. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Ketone Hydrochloride
137. 6-hydroxy-2-(p-hydroxyphenyl)benzo(.beta.)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride
138. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(.beta.)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride
139. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, Hydrochloride (1:1)
140. Raloxifene Hydrochloride For Peak Identification, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 510.0 g/mol |
---|---|
Molecular Formula | C28H28ClNO4S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 7 |
Exact Mass | 509.1427572 g/mol |
Monoisotopic Mass | 509.1427572 g/mol |
Topological Polar Surface Area | 98.2 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 655 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Evista |
PubMed Health | Raloxifene (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Lilly |
2 of 4 | |
---|---|
Drug Name | Raloxifene hydrochloride |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Tentative Approval; Prescription |
Company | Teva Pharms Usa; Invagen Pharms; Watson Labs |
3 of 4 | |
---|---|
Drug Name | Evista |
PubMed Health | Raloxifene (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Lilly |
4 of 4 | |
---|---|
Drug Name | Raloxifene hydrochloride |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Tentative Approval; Prescription |
Company | Teva Pharms Usa; Invagen Pharms; Watson Labs |
Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5. 1).
Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Selective Estrogen Receptor Modulators
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Estrogen Antagonists
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)
G03XC01
G03XC01
G03XC01
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-02
Pay. Date : 2013-03-22
DMF Number : 16143
Submission : 2002-09-23
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2014-04-29
Pay. Date : 2014-02-24
DMF Number : 27969
Submission : 2014-03-17
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21327
Submission : 2008-02-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21650
Submission : 2008-05-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24589
Submission : 2011-02-01
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-07-05
Pay. Date : 2015-09-24
DMF Number : 22927
Submission : 2009-07-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20163
Submission : 2007-01-17
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-10-05
Pay. Date : 2015-09-25
DMF Number : 15932
Submission : 2002-04-10
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-03-04
Pay. Date : 2013-09-05
DMF Number : 21682
Submission : 2008-06-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-06-12
Pay. Date : 2018-05-25
DMF Number : 25281
Submission : 2011-09-06
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Certificate Number : R1-CEP 2014-054 - Rev 01
Status : Valid
Issue Date : 2023-03-31
Type : Chemical
Substance Number : 2375
Raloxifene Hydrochloride, Modified Process
Certificate Number : CEP 2024-069 - Rev 00
Status : Valid
Issue Date : 2024-04-24
Type : Chemical
Substance Number : 2375
Certificate Number : CEP 2012-016 - Rev 02
Status : Valid
Issue Date : 2024-01-05
Type : Chemical
Substance Number : 2375
Certificate Number : CEP 2022-165 - Rev 00
Status : Valid
Issue Date : 2024-04-22
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2010-205 - Rev 00
Status : Valid
Issue Date : 2017-09-06
Type : Chemical
Substance Number : 2375
Raloxifene Hydrochloride, LAXAI
Certificate Number : CEP 2023-123 - Rev 00
Status : Valid
Issue Date : 2023-11-29
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2010-227 - Rev 01
Status : Valid
Issue Date : 2019-10-15
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2011-349 - Rev 00
Status : Valid
Issue Date : 2020-11-30
Type : Chemical
Substance Number : 2375
Certificate Number : R0-CEP 2015-174 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2016-11-02
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2015-171 - Rev 00
Status : Valid
Issue Date : 2022-04-08
Type : Chemical
Substance Number : 2375
Registration Number : 228MF10113
Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad Telangana, India
Initial Date of Registration : 2016-06-17
Latest Date of Registration : 2016-06-17
Registration Number : 227MF10039
Registrant's Address : Via Curiel 34, 20067 Paulo, Milano, ITALY
Initial Date of Registration : 2015-02-09
Latest Date of Registration : 2015-02-09
Registration Number : 226MF10007
Registrant's Address : VIA F. BARACCA 19-24060 SAN PAOLO D'ARGON (BERGAMO) ITALY
Initial Date of Registration : 2014-01-08
Latest Date of Registration : 2014-11-17
Raloxifene hydrochloride hydrate
Registration Number : 227MF10053
Registrant's Address : 57, Gyeongje-ro, Siheung-si, Gyeonggi-do, Korea
Initial Date of Registration : 2015-02-18
Latest Date of Registration : 2015-02-18
Raloxifene hydrochloride hydrate
Registration Number : 227MF10048
Registrant's Address : 174, Sirok-ro, Asan-si, Chungcheongnam-do, KOREA
Initial Date of Registration : 2015-02-09
Latest Date of Registration : 2023-09-20
Registration Number : 303MF10064
Registrant's Address : Strada Rivoltana Km. 6/7 20053 Rodano (MI), Italy
Initial Date of Registration : 2021-04-13
Latest Date of Registration : 2021-04-13
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Raloxifene Hydrochloride USP/Ph. Eur.
Date of Issue : 2025-07-25
Valid Till : 2028-06-16
Written Confirmation Number : WC-0034
Address of the Firm : Unit II, Plot Nos. 1, 75A, 75B, 105, 110, 111 & 112, Sri Venkateswara Co-operati...
Date of Issue : 2022-08-10
Valid Till : 2025-05-08
Written Confirmation Number : WC-0219
Address of the Firm : Plot No. E-22, MIDC Tarapur-Boisar, Thane-401506, Maharashtra, India
Raloxifene Hydrochloride Ph.Eur
Date of Issue : 07-11-2025
Valid Till : 25-06-2028
Written Confirmation Number : WC-0023
Address of the Firm : Sy. No’s. 52,53,58,59,61 to 78, 127 & 128,Pydibhimavaram Village & Sy. No’s....
Raloxefene hydrochloride Ph.Eur/USP
Date of Issue : 2022-09-19
Valid Till : 2025-07-02
Written Confirmation Number : WC-0119
Address of the Firm : Plot No. 35, 36, 38, 39, 40, 49, 50 & 51, Phase-IV, IDA, Jeedimetla, Medchal-Mal...
Date of Issue : 2022-09-01
Valid Till : 2025-07-02
Written Confirmation Number : WC-0074Amended
Address of the Firm : 294, GIDC Estate Ankleshwar, Bharuch-393002, Gujarat India
Raloxifene Hydrochloride USP/Ph.Eur
Date of Issue : 2022-09-30
Valid Till : 2025-08-08
Written Confirmation Number : WC-0066
Address of the Firm : Plot No 1, Hetero Infrastructure SEZ Ltd., N. Narasapuram, Anakapalli -531081, A...
Date of Issue : 2023-07-24
Valid Till : 2026-08-23
Written Confirmation Number : WC-0381
Address of the Firm : Plot No. 98-99, Sector-1, Industrial Area Pithampur, Dhar-454775, Madhya Pradesh...
Raloxifene Hydrochloride BP/Ph. Eur
Date of Issue : 2023-07-10
Valid Till : 2025-05-21
Written Confirmation Number : WC-0313
Address of the Firm : SurveyNo.247,Choutuppal, Choutuppal (V),Choutuppal (M),YadadriBhuvanagiri Distri...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Alvogen Korea Co., Ltd.
Registration Date : 2020-09-17
Registration Number : 20200917-209-J-745
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri V...
Registrant Name : Medipoem Co., Ltd.
Registration Date : 2025-06-23
Registration Number : 20231218-209-J-1584(A)
Manufacturer Name : Aurore Pharmaceuticals Priva...
Manufacturer Address : Plot No. 35, 36, 38 to 40 & 49 to 51 Phase-IV, IDA, Jeedimetla, Hyderabad Telangana, ...
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2020-08-13
Registration Number : 20200813-209-J-694
Manufacturer Name : Cambrex Profarmaco Milano Sr...
Manufacturer Address : Via Curiel, 34 – 20067 Paullo (Milan) Italy
Raloxifene hydrochloride monohydrate
Registrant Name : Dasan Pharmaceutical Co., Ltd.
Registration Date : 2017-11-07
Registration Number : 20171107-209-J-123
Manufacturer Name : Dasan Pharmaceutical Co., Lt...
Manufacturer Address : 342 Deokamsan-ro, Dogomyeon, Asan-si, Chungcheongnam-do @ 28, Yakjakgongdan 2-gil, Hy...
Registrant Name : Hanmi Precision Chemical Co., Ltd.
Registration Date : 2022-10-24
Registration Number : 20221024-209-J-1389
Manufacturer Name : Hanmi Precision Chemical Co....
Manufacturer Address : 57 Gyeongje-ro, Siheung-si, Gyeonggi-do (1248-10)
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2021-10-14
Registration Number : 20211014-209-J-1021
Manufacturer Name : Hetero Drugs Limited(Unit-IX...
Manufacturer Address : Plot No.1, Hetero Infrastructure-SEZ Ltd, N. Narasapuram Village, Nakkapalli Mandal, ...
Registrant Name : Kyungbo Pharmaceutical Co., Ltd.
Registration Date : 2018-02-27
Registration Number : 20180227-209-J-77
Manufacturer Name : Kyungbo Pharmaceutical Co., ...
Manufacturer Address : 174 Silok-ro, Asan-si, Chungcheongnam-do
Registrant Name : Engichem Life Sciences Co., Ltd.
Registration Date : 2020-07-16
Registration Number : 20200716-209-J-693
Manufacturer Name : Engichem Life Sciences Co., ...
Manufacturer Address : 59 Biovalley-ro, Jecheon-si, Chungcheongbuk-do
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Regulatory Info :
Registration Country : Australia
Brand Name : Fixta 60
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Fixta 60
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Canada
Brand Name : APO-RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging : 100
Approval Date :
Application Number : 2279215
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Brand Name : RALOVISTA
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : USA
Brand Name : EVISTA
Dosage Form : TABLET; ORAL
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number : 22042
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Tablet
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Regulatory Info :
Registration Country : Italy
Brand Name : Raloxifene
Dosage Form : Raloxifene 60Mg 28 Combined Oral Use
Dosage Strength : 28 cpr riv 60 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Loxitrin
Dosage Form : TAB
Dosage Strength : 60mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info :
Registration Country : Spain
Brand Name : Raloxifene Kern Pharma 60Mg 28 Coated Tablets Efg
Dosage Form : Coated Tablet
Dosage Strength : 60 Mg/Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2015-01-21
Application Number : 200825
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2016-04-08
Application Number : 208206
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2015-08-28
Application Number : 204310
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : EVISTA
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 1997-12-09
Application Number : 20815
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD :
TE Code :
Brand Name : EVISTA
Dosage Form : TABLET; ORAL
Dosage Strength : 60MG
Approval Date :
Application Number : 22042
RX/OTC/DISCN :
RLD :
TE Code :
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2016-03-22
Application Number : 204491
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2014-09-24
Application Number : 90842
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2016-10-12
Application Number : 206384
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2014-03-04
Application Number : 78193
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2020-08-18
Application Number : 211324
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Regulatory Info :
Registration Country : Italy
Brand Name : Optruma
Dosage Form : Raloxifene 60Mg 28 Combined Oral Use
Dosage Strength : 28 cpr riv 60 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : Generic US CTD
Registration Country : United Kingdom
Brand Name :
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number : 200825
Regulatory Info : Generic US CTD
Registration Country : United Kingdom
Regulatory Info :
Registration Country : Italy
Brand Name : Raloxifene
Dosage Form : Raloxifene 60Mg 14 Joined' Oral Use
Dosage Strength : 14 cpr riv 60 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Brand Name : Raloxifene STADA
Dosage Form : FILM COATED PILL
Dosage Strength : 60 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Spain
Brand Name : Raloxifene Kern Pharma 60Mg 28 Coated Tablets Efg
Dosage Form : Coated Tablet
Dosage Strength : 60 Mg/Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : 28 Stada Raloxifene 60Mg Film-Coated Tablets Efg
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : Evista 60Mg Film-Coated Tablets 28 C
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : 28 Sandoz Raloxifene 60Mg Film-Coated Tablets Efg
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Evista
Dosage Form : Antic-calc Tablet
Dosage Strength : 60 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Evista
Dosage Form : Antic-calc Tablet
Dosage Strength : 60 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Canada
Brand Name : APO-RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging : 100
Approval Date :
Application Number : 2279215
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : EVISTA
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging : 28
Approval Date :
Application Number : 2239028
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : JAMP RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number : 2540681
Regulatory Info :
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PMS-RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging : 30/100
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : ACT RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number : 2358840
Regulatory Info :
Registration Country : Canada
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
42
PharmaCompass offers a list of Raloxifene Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Raloxifene Hydrochloride manufacturer or Raloxifene Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Raloxifene Hydrochloride manufacturer or Raloxifene Hydrochloride supplier.
PharmaCompass also assists you with knowing the Raloxifene Hydrochloride API Price utilized in the formulation of products. Raloxifene Hydrochloride API Price is not always fixed or binding as the Raloxifene Hydrochloride Price is obtained through a variety of data sources. The Raloxifene Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride, including repackagers and relabelers. The FDA regulates [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride supplier is an individual or a company that provides [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride active pharmaceutical ingredient (API) or [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride finished formulations upon request. The [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers may include [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride DMFs exist exist since differing nations have different regulations, such as [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride USDMF includes data on [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride Drug Master File in Japan ([6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride JDMF) empowers [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride Drug Master File in Korea ([6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride. The MFDS reviews the [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride KDMF as part of the drug registration process and uses the information provided in the [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers with KDMF on PharmaCompass.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride Certificate of Suitability (COS). The purpose of a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride to their clients by showing that a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEP has been issued for it. The manufacturer submits a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEP holder for the record. Additionally, the data presented in the [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride DMF.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride written confirmation ([6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride WC) is an official document issued by a regulatory agency to a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride manufacturer, verifying that the manufacturing facility of a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride APIs or [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride suppliers with NDC on PharmaCompass.
[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride GMP manufacturer or [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride GMP API supplier for your needs.
A [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride's compliance with [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride specifications and serves as a tool for batch-level quality control.
[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia ([6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride EP), [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia ([6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride USP).